Cargando…

A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab

AIM: Assessing the incidence of Medication Related Osteonecrosis of the Jaw (MRONJ) in cancer patients with bone metastases receiving Denosumab (Dmab) and identifying potential risk factors. METHODS: A retrospective observational study on consecutive cancer patients with bone metastases, who receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bracchi, Paola, Zecca, Ernesto, Brunelli, Cinzia, Miceli, Rosalba, Tinè, Gabriele, Maniezzo, Massimo, Lo Dico, Silvia, Caputo, Mariangela, Shkodra, Morena, Caraceni, Augusto T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523953/ https://www.ncbi.nlm.nih.gov/pubmed/37559413 http://dx.doi.org/10.1002/cam4.6429

Ejemplares similares

Cancer pain: Results of a prospective study on prognostic indicators of pain intensity including pain syndromes assessment
por: Shkodra, Morena, et al.
Publicado: (2022)

Neuropathic pain: clinical classification and assessment in patients with pain due to cancer
por: Shkodra, Morena, et al.
Publicado: (2021)

Telemedicine for outpatient palliative care during COVID-19 pandemics: a longitudinal study
por: Caraceni, Augusto, et al.
Publicado: (2022)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol
por: Brunelli, Cinzia, et al.
Publicado: (2022)

Denosumab Related Osteonecrosis of Jaw: a Case Report
por: de Sales Lima, Marco Vinícius, et al.
Publicado: (2018)

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Cancer Pain Assessment and Classification
por: Caraceni, Augusto, et al.
Publicado: (2019)

Treatment of Neuropathic Pain Directly Due to Cancer: An Update
por: Shkodra, Morena, et al.
Publicado: (2022)

Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
por: Neuprez, A., et al.
Publicado: (2013)

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
por: Yoshimura, Hitoshi, et al.
Publicado: (2017)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Characterizing Different Multidisciplinary Team Models Implemented Within One Comprehensive Cancer Center
por: Alfieri, Sara, et al.
Publicado: (2023)

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
por: Okuma, Satoe, et al.
Publicado: (2020)

384. Denosumab-Related Osteonecrosis of the Jaw: an Emergent and Potentially Complex Bone and Joint Infection
por: Bricca, Romain, et al.
Publicado: (2019)

Denosumab/ibandronic acid/zoledronic acid: Medication-related osteonecrosis of jaw: case report
Publicado: (2021)

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
por: Wick, Alexander, et al.
Publicado: (2021)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review
por: de Oliveira, Camila-Carvalho, et al.
Publicado: (2016)

Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases
por: Tofé, Victoria I., et al.
Publicado: (2020)

Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain
por: Brunelli, Cinzia, et al.
Publicado: (2010)

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case
por: Qaisi, Mohammed, et al.
Publicado: (2016)

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study
por: Assili, Zineb, et al.
Publicado: (2021)

Development of the palliative care referral system: proposal of a tool for the referral of cancer patients to specialized palliative care
por: Pigni, Alessandra, et al.
Publicado: (2022)

Osteonecrosis of the Jaw
por: Lončar Brzak, Božana, et al.
Publicado: (2023)

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients
por: Jung, Seoyeon, et al.
Publicado: (2022)

Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data(): Medical ozone gas insufflation in treating ONJ lesions
por: Ripamonti, C.I., et al.
Publicado: (2012)

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)
por: Fusco, Vittorio, et al.
Publicado: (2022)

Bisphophonates related osteonecrosis of the jaw
por: Gupta, Swati, et al.
Publicado: (2013)

Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience
por: Favia, Gianfranco, et al.
Publicado: (2016)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis
por: Limones, Alvaro, et al.
Publicado: (2020)

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
por: Liu, Fang-Chun, et al.
Publicado: (2023)

Osteonecrosis of jaw associated with bisphosphonate use
por: Rastogi, Ashu, et al.
Publicado: (2012)

Bisphosphonate-related osteonecrosis of the jaws (Bronj)
por: Beninati, Francesco, et al.
Publicado: (2013)

Osteonecrosis of the jaws in patients treated with bisphosphonates
por: Ata-Ali, Fadi, et al.
Publicado: (2012)

Bisphosphonate-Related Osteonecrosis of the Jaw: Specificities
por: Paulo, Siri, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_roma2uhpkbp0ncb2fb0h3st0b3